Home News JUST IN: Popular Nigerian Senator, Ifeanyi Ubah Dies In London
NewsPolitics

JUST IN: Popular Nigerian Senator, Ifeanyi Ubah Dies In London

423
JUST IN: Popular Nigerian Senator, Ifeanyi Ubah Dies In London

The popular Nigerian Senator representing Anambra South District in the 10th National Assembly, Ifeanyi Ubah, has reportedly died in a hotel in London, the United Kingdom.

According to SaharaReporters, Ubah visited London two days ago, where he died. His passing was confirmed in a group chat on an unnamed social media platform, where tributes are already pouring in for the deceased.

The lawmaker’s demise comes days after his campaign council reportedly donated 71 million to the All Progressives Congress (APC) ruling party in Anambra state to support the party’s reach ahead of the 2025 governorship election.

Ubah was billed to seek the APC ticket to contest next year’s Anambra State governorship election.

With the news of the demised, the Senate has yet to make a public announcement.

The story is still developing…

Read More:

About The Author

Written by
Mayowa Durosinmi

M. Durosinmi is a West Africa Weekly investigative reporter covering Politics, Human Rights, Health, and Security in West Africa and the Sahel Region

Related Articles

Jamb UTME 2025
EducationNews

JAMB Orders Review of 2025 UTME After Public Outcry Over Mass Failure, Technical Issues

The Joint Admissions and Matriculation Board (JAMB) has announced an immediate review...

Tinubu newly appointed INEC members
Politics

Tinubu Appoints New INEC Commissioners and Board Members, Shifts Focus to 2027 Elections Amid Economic Hardship

President Bola Tinubu has administered the oath of office to newly appointed...

NewsSports

Flying Eagles Reach AFCON U-20 Semi-Finals, Secure 2025 FIFA U-20 World Cup Spot After Dramatic Win Over Senegal

Nigeria’s Flying Eagles have sealed their qualification for the 2025 FIFA U-20...

HealthNews

Nigerians May Pay More for Medicines After Trump’s Pharmaceutical Price Cuts

Nigerians may pay more for prescription drugs following President Donald Trump’s announcement...